Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer
NCT04655365Phase 2Completed
- Sponsor
- CHU de Québec-Université Laval
- Start
- Mar 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of piflufolastat f 18 in prostate cancer (PCa), sponsored by CHU de Québec-Université Laval. Started Mar 2022; status: completed.
02
Drugs
piflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04655365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655365.